• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Monday, January 30, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

Q&A With Kasha Witkos, SVP, Head Of International Region, Alnylam Pharmaceuticals

by NewsReporter
March 7, 2022
in Cambridge
q&a-with-kasha-witkos,-svp,-head-of-international-region,-alnylam-pharmaceuticals
Share on FacebookShare on Twitter

Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.

Alnylam (Cambridge, MA) is a RNAi therapeutics company whose ONPATTRO® (patisiran) became the world’s first approved RNAi therapeutic in 2018. Since then, the company’s RNAi therapeutics GIVLAARI® and OXLUMO® (lumasiran) have received approval. Alnylam continues to advance a pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Kasha Witkos joined Alnylam at the end of 2020, the same time as Chief Commercial Officer Tolga Tanguler (who is interviewed by Pharm Exechere). Witkos started her medical education at Medical Academy of Wroclaw, Poland, before transferring to the University of Colorado at Boulder, where she completed her degree in genetics. Prior to Alnylam, she held several commercial roles in rare diseases at Takeda and its legacy organizations (Baxter, Baxalta, Shire). Here, Witkos talks to Pharm Exec about her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.

Pharm Exec: What motivated you to join Alnylam Pharmaceuticals?

Witkos: I joined Alnylam Pharmaceuticals a year ago and am responsible for Europe, Canada, and Japan. With a background in science and genetics, I have always been interested in the concept of gene silencing. Being able to take it from plants to animals to human health is truly fascinating. As a company, we can impact so many potential disease areas—and patients in need—through gene silencing, and that’s what excited me and drew me to Alnylam in the first place.

The culture of the company is also something which is unique, informed by our “Challenge Accepted” mindset. As a business, we have faced—and as every business does, will continue to face—many challenges, but we believe that patients shouldn’t have to wait for hope, that every “no” takes us one step closer to “yes.” Pioneering science combined with the right mindset and innovative culture are very powerful.

Pharm Exec: What have been your key priorities since joining?

Witkos: When I joined, I wanted to build on the strong foundations already in place as well as maintain the collaborative culture that has been built over time.At Alnylam, we embrace big ambitions with our P5x25 mission and aim to become one of the top five biotechs globally by 2025.

Our focus is on bringing new medicines to patients with more prevalent conditions such as hypertension, nonalcoholic steatohepatitis, gout, and Alzheimer’s. We intend to build on our learnings from rare disease and apply our innovations to develop new first-in-class or best-in-class medicines for targeted disease indications.

Pharm Exec: Alnylam is hoping to achieve a company profile rarely achieved in the biotech sector. What are the biggest risks to achieving these ambitious goals?

Witkos: You’re right. We are firmly focused on growth of our portfolio and pipeline. We’re committed to our P5x25 strategy while maintaining a laser focus on patients: What are their needs and how can we improve their outcomes?

As we scale the company to deliver these ambitions, it’s critical that we maintain the values and culture that make this such a special place to work: our “biotech grit,” hunger for success, and focus on innovation across the organization.

Excitingly, Alnylam retains many qualities of a startup and we work with an entrepreneurial mindset. We have an opportunity now to influence and improve outcomes for thousands of patients around the world, but we also have to consider our roadmap to growth carefully. We need to retain and protect the values that set Alnylam apart, but also plan for how our business will evolve and what impact that may have.

Pharm Exec: You talk about growth and scaling up of Alnylam to meet your ambitious goals. What does this mean for Alnylam’s culture?

Witkos: Recognizing the contribution that culture plays, we are invested in building and shaping it. We know that our collaborative, patient-focused, and innovative mindset drives how we act and deliver for patients, and so we work hard to make sure our new hires understand and embrace it from their first day.

If you want to be part of an organization that aims to change the trajectory of healthcare, then you are by nature a “change the world” kind of person. We think we do a great job of ensuring our culture works and is the reason for our success. We are regularly recognized across Europe as a great place to work, and last year our team in Switzerland was ranked No. 1 as best small workplace. Our internal culture survey highlights positive employee feedback across a variety of areas, including how we live and uphold our core values, how we embrace a patient-focused mindset, our sense of community and camaraderie, and our pride and motivation in the work we do. Of course, there are also areas we need to strengthen and build upon, so understanding our employee perspectives and experience is critical to help us do that.

Integral to our work in promoting a culture that drives individual and business success is our commitment to diversity, equity, and inclusion.

Pharm Exec: What is your long-term ambition for Alnylam culture in the DE&I space?

Witkos: Diversity, equity, and inclusion is not a nice-to-do, it’s a right-to-do, and it has a clear impact on our continued success as we grow and evolve. We are committed to embrace and embed DE&I across every function and build a globally inclusive and bias-free company where everyone can fulfil their potential. Our employee resource networks focus on different aspects of DE&I and all our employees are empowered to be part of these networks. DE&I starts with our leaders and is the responsibility of every member of the organization. Being curious and educating ourselves about diversity makes us better colleagues, better managers, better leaders, and better people.

As an organization committed to meeting the needs of patients, it’s imperative that our business reflects the diverse world we live in. We also know that if we are to continue to innovate, we need to bring together people with diverse perspectives and lived experience, who can respectfully challenge themselves, each other, and the status quo. It’s on us to pay attention and listen, and to be in a position to speak up when it’s required.

There are also some practical aspects to DE&I—for example, our focus on increasing clinical trial recruitment and retention among minority ethnic communities, to generate data that is more reflective of the overall patient populations we are aiming to reach with our transformative therapies. We’re guided by our patient access philosophy: No patient should have to wait for hope.

Pharm Exec: How is Alnylam going to maintain its leadership in the RNAi field with so many large and small companies interested in this area? What strategic shifts have you seen with a new CEO coming on board?

Witkos: Alnylam’s new CEO, Dr. Yvonne Greenstreet, has been at Alnylam for six years and has played a huge part in developing our business strategy and culture, so we don’t expect a change in direction. She brings a vast amount of experience, having previously worked across diverse markets and various areas of pharma, including medical, R&D, and regulatory, which gives her a uniquely well-rounded perspective.

Alnylam is still the only company that has both developed and commercialized an RNAi therapeutic, and that’s something we can be very proud of. More broadly, the growth of RNAi therapeutics is a validation of the pioneering work we’ve already done. Patients are waiting for treatment and we’re confident in the potential of our pipeline to meet their needs with an entirely new standard of care.

Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT